These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 33836159)

  • 1. New treatment regimens for Chagas disease: light at the end of the tunnel?
    Morillo CA; Echeverria LE
    Lancet Infect Dis; 2021 Aug; 21(8):1057-1058. PubMed ID: 33836159
    [No Abstract]   [Full Text] [Related]  

  • 2. Antitrypanosomal Activity of Sterol 14α-Demethylase (CYP51) Inhibitors VNI and VFV in the Swiss Mouse Models of Chagas Disease Induced by the Trypanosoma cruzi Y Strain.
    Guedes-da-Silva FH; Batista DG; Da Silva CF; De Araújo JS; Pavão BP; Simões-Silva MR; Batista MM; Demarque KC; Moreira OC; Britto C; Lepesheva GI; Soeiro MN
    Antimicrob Agents Chemother; 2017 Apr; 61(4):. PubMed ID: 28167559
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The uniqueness of the Trypanosoma cruzi mitochondrion: opportunities to identify new drug target for the treatment of Chagas disease.
    Lisvane Silva P; Mantilla BS; Barisón MJ; Wrenger C; Silber AM
    Curr Pharm Des; 2011; 17(20):2074-99. PubMed ID: 21718252
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An update on benznidazole for the treatment of patients with Chagas disease.
    Thakare R; Dasgupta A; Chopra S
    Drugs Today (Barc); 2018 Jan; 54(1):15-23. PubMed ID: 29569658
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Trypanosoma cruzi genetic diversity: Something new for something known about Chagas disease manifestations, serodiagnosis and drug sensitivity.
    Zingales B
    Acta Trop; 2018 Aug; 184():38-52. PubMed ID: 28941731
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A new chemotype with promise against Trypanosoma cruzi.
    Wang X; Cal M; Kaiser M; Buckner FS; Lepesheva GI; Sanford AG; Wallick AI; Davis PH; Vennerstrom JL
    Bioorg Med Chem Lett; 2020 Jan; 30(1):126778. PubMed ID: 31706668
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Drug Discovery for Paediatric Chagas Disease.
    Thota S; Morel CM
    Mini Rev Med Chem; 2018; 18(9):776-780. PubMed ID: 26202205
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inositol metabolism in Trypanosoma cruzi: potential target for chemotherapy against Chagas' disease.
    Oliveira MM; Einicker-Lamas M
    An Acad Bras Cienc; 2000 Sep; 72(3):413-9. PubMed ID: 11028106
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Amiodarone and Trypanosoma cruzi parasitemia in patients with Chagas disease.
    Carmo AA; Rocha MO; Silva JL; Ianni BM; Fernandes F; Sabino EC; Ribeiro AL
    Int J Cardiol; 2015 Jun; 189():182-4. PubMed ID: 25897900
    [No Abstract]   [Full Text] [Related]  

  • 10. [Treatment of Chagas disease. New schemes].
    Apt W; Zulantay I; Salas P
    Rev Med Chil; 2022 Dec; 150(12):1689-1690. PubMed ID: 37906792
    [No Abstract]   [Full Text] [Related]  

  • 11. [New insights into pathophysiology and treatment in Chagas-Mazza disease].
    Rivarola HW; Paglini-Oliva P
    Rev Fac Cien Med Univ Nac Cordoba; 2011; 68(4):154-63. PubMed ID: 22668568
    [No Abstract]   [Full Text] [Related]  

  • 12. Chagas Disease: A Solvable Problem, Ignored.
    Tarleton RL
    Trends Mol Med; 2016 Oct; 22(10):835-838. PubMed ID: 27523778
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of benznidazole treatment on the functional response of Trypanosoma cruzi antigen-specific CD4+CD8+ T cells in chronic Chagas disease patients.
    Pérez-Antón E; Egui A; Thomas MC; Puerta CJ; González JM; Cuéllar A; Segovia M; López MC
    PLoS Negl Trop Dis; 2018 May; 12(5):e0006480. PubMed ID: 29750791
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of carbonic anhydrase from Trypanosoma cruzi for the management of Chagas disease: an underexplored therapeutic opportunity.
    Supuran CT
    Future Med Chem; 2016; 8(3):311-24. PubMed ID: 26898220
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Use of a recombinant Trypanosoma cruzi protein antigen to monitor cure of Chagas disease.
    Guevara AG; Taibi A; Alava J; Guderian RH; Ouaissi A
    Trans R Soc Trop Med Hyg; 1995; 89(4):447-8. PubMed ID: 7570896
    [No Abstract]   [Full Text] [Related]  

  • 16. Persistent infections in chronic Chagas' disease patients treated with anti-Trypanosoma cruzi nitroderivatives.
    Braga MS; Lauria-Pires L; Argañaraz ER; Nascimento RJ; Teixeira AR
    Rev Inst Med Trop Sao Paulo; 2000; 42(3):157-61. PubMed ID: 10887376
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [A case of chagas infection caused by an atypical strain of Trypanosoma cruzi in a newborn infant].
    de Storni P; Bakos E; Bustamante A; Vanioff JA
    Medicina (B Aires); 1984; 44(3):287-91. PubMed ID: 6443628
    [No Abstract]   [Full Text] [Related]  

  • 18. Combined use of ascorbic acid and cyanocobalamin in clearance of Trypanosoma cruzi.
    Ghobadifar MA; Kalani N; Gitiforouz M
    Expert Rev Clin Pharmacol; 2014 Jul; 7(4):401-2. PubMed ID: 24857404
    [No Abstract]   [Full Text] [Related]  

  • 19. Structure-activity relationship of 4-azaindole-2-piperidine derivatives as agents against Trypanosoma cruzi.
    Koovits PJ; Dessoy MA; Matheeussen A; Maes L; Caljon G; Mowbray CE; Kratz JM; Dias LC
    Bioorg Med Chem Lett; 2020 Jan; 30(1):126779. PubMed ID: 31706667
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Trypanothione Reductase: A Target for the Development of Anti- Trypanosoma cruzi Drugs.
    Vázquez K; Paulino M; Salas CO; Zarate-Ramos JJ; Vera B; Rivera G
    Mini Rev Med Chem; 2017; 17(11):939-946. PubMed ID: 28302040
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.